The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) have started taking the drug today.
Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, head of the drug's clinical trial program Cao Bin said.
A total of 761 patients have been enrolled in the trials, which will adopt a randomised, double-blind and placebo-controlled study method, Xinhua reported.
The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), are conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital.
Wuhan starts using antiviral drug in clinical trials against coronavirus - media
4975 views
